Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2016-08-10 Earnings Release
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Earnings Release 2016
Earnings Release Classification · 98% confidence The document provides a summary of financial performance for the first half of 2016 (1. halvår 2016), including sales growth, operating profit margin, net income, and updated guidance for the full year 2016 (Forventning til indtjening i 2016 fastholdes). It highlights key financial metrics and management commentary. This structure—a concise summary of period results and updated outlook—is characteristic of an Earnings Release (ER). The final line, 'Læs hele meddelelsen i PDF format' (Read the full announcement in PDF format), suggests this text is the summary announcement, not the comprehensive report itself, reinforcing the ER classification over a full Interim Report (IR) or Annual Report (10-K). H1 2016
2016-08-10 Danish
Interim / Quarterly Report 2016
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the first half of 2016' and contains comprehensive financial statements, performance analysis, segment breakdowns, and outlook data for the first half of the fiscal year. It is not a mere announcement or certification, but the substantive report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2016
2016-08-10 English
Delårsrapport for 1. halvår 2016
Earnings Release Classification · 90% confidence The document is a concise summary of half-year financial performance and outlook adjustments, featuring key metrics (organic sales growth, EBIT, net profit) and management commentary, ending with a pointer to a full PDF. This matches the characteristics of an initial Earnings Release, providing headline quarterly/period results and outlook rather than full financial statements or a detailed report. Thus, it should be classified as an Earnings Release (ER). H1 2016
2016-08-10 English
Delårsrapport for 1. halvår 2016
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the first half of 2016 for Novozymes A/S. It contains comprehensive financial statements, management analysis of business segments, balance sheet data, cash flow information, and sustainability metrics. It is clearly a substantive financial report for a period shorter than a full fiscal year, not merely an announcement or a certification. Therefore, it fits the definition of an Interim/Quarterly Report (IR). H1 2016
2016-08-10 English
Transaction in Own Shares 2016
Transaction in Own Shares Classification · 100% confidence The document text explicitly states that Novozymes has purchased an accumulated number of shares under a stock buyback program, referencing a previous company announcement. This action—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. The document length is very short (281 chars) and it directs the reader to 'Read the full announcement in PDF', which suggests it might be a brief notification, but the core content is a direct report of a share transaction, making POS the most specific fit over RPA or RNS.
2016-08-08 English
Transaction in Own Shares 2016
Transaction in Own Shares Classification · 98% confidence The document explicitly details 'Transactions under Novozymes' stock buyback program' and provides daily transaction data (number of shares, average purchase price, transaction value) for the period August 1 to August 5, 2016. It also mentions the total accumulated shares purchased under the program. This content directly relates to the company repurchasing or dealing in its own shares. According to the definitions, 'Transaction in Own Shares (Code: POS)' covers 'Report of the company buying back or selling its own shares (share repurchase/issuance)'. Although 'Director's Dealing (DIRS)' covers executive trades, this document focuses on the corporate stock buyback program, making POS the most accurate classification.
2016-08-08 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.